Do analysts rate INDV or BMY?

Bloomsbury Publishing has a consensus target price of GBX 800, suggesting a potential upside of 22.32%. Given Bloomsbury Publishing's stronger consensus rating and higher possible upside, analysts plainly believe Bloomsbury Publishing is more favorable than Indivior. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indivior 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bloomsbury Publishing 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media favor INDV or BMY?

In the previous week, Indivior and Indivior both had 1 articles in the media. Indivior's average media sentiment score of 0.75 equaled Bloomsbury Publishing'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bloomsbury Publishing 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer HCM or BMY?

Bloomsbury Publishing has a consensus target price of GBX 800, indicating a potential upside of 22.32%. Given Bloomsbury Publishing's stronger consensus rating and higher possible upside, analysts plainly believe Bloomsbury Publishing is more favorable than HUTCHMED. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bloomsbury Publishing 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts prefer VEC or BMY?

Bloomsbury Publishing has a consensus price target of GBX 800, suggesting a potential upside of 22.32%. Given Bloomsbury Publishing's stronger consensus rating and higher possible upside, analysts plainly believe Bloomsbury Publishing is more favorable than Vectura Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vectura Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bloomsbury Publishing 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate BMY or ERGO?

Bloomsbury Publishing presently has a consensus target price of GBX 800, indicating a potential upside of 22.32%. Given Bloomsbury Publishing's stronger consensus rating and higher probable upside, equities analysts clearly believe Bloomsbury Publishing is more favorable than Ergomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bloomsbury Publishing 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Ergomed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Bloomsbury Publishing (BMY) Competitors

GBX 654 +11.00 (+1.71%)

As of 08/21/2026 12:28 PM Eastern

Compare

BMY vs. INDV, HCM, VEC, ERGO, and AMYT

Should you buy Bloomsbury Publishing stock or one of its competitors? Bloomsbury Publishing's main competitors and comparable companies include Indivior (INDV), HUTCHMED (HCM), Vectura Group (VEC), Ergomed (ERGO), and Amryt Pharma (AMYT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Bloomsbury Publishing compare to Indivior?

Indivior (LON:INDV) and Bloomsbury Publishing (LON:BMY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Bloomsbury Publishing has lower revenue, but higher earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Bloomsbury Publishing, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	£1.40B	1.38	-£2.36M	-£1.21	N/A
Bloomsbury Publishing	£325.90M	1.62	£37.37M	£32.80	19.94

Bloomsbury Publishing has a consensus target price of GBX 800, suggesting a potential upside of 22.32%. Given Bloomsbury Publishing's stronger consensus rating and higher possible upside, analysts plainly believe Bloomsbury Publishing is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bloomsbury Publishing	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Indivior has a net margin of 11.44% compared to Bloomsbury Publishing's net margin of 8.28%. Bloomsbury Publishing's return on equity of 12.74% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	11.44%	-23.90%	2.37%
Bloomsbury Publishing	8.28%	12.74%	7.82%

86.0% of Indivior shares are owned by institutional investors. Comparatively, 42.2% of Bloomsbury Publishing shares are owned by institutional investors. 3.4% of Indivior shares are owned by company insiders. Comparatively, 3.6% of Bloomsbury Publishing shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Indivior and Indivior both had 1 articles in the media. Indivior's average media sentiment score of 0.75 equaled Bloomsbury Publishing'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bloomsbury Publishing	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indivior has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Bloomsbury Publishing has a beta of 0.418, indicating that its share price is 58% less volatile than the broader market.

Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. Bloomsbury Publishing pays an annual dividend of GBX 15.62 per share and has a dividend yield of 2.4%. Indivior pays out -1,243.7% of its earnings in the form of a dividend. Bloomsbury Publishing pays out 47.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Bloomsbury Publishing beats Indivior on 12 of the 16 factors compared between the two stocks.

How does Bloomsbury Publishing compare to HUTCHMED?

HUTCHMED (LON:HCM) and Bloomsbury Publishing (LON:BMY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Bloomsbury Publishing has lower revenue, but higher earnings than HUTCHMED. Bloomsbury Publishing is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	£549.12M	2.91	-£52.98M	£2.00	92.00
Bloomsbury Publishing	£325.90M	1.62	£37.37M	£32.80	19.94

20.3% of HUTCHMED shares are owned by institutional investors. Comparatively, 42.2% of Bloomsbury Publishing shares are owned by institutional investors. 2.8% of HUTCHMED shares are owned by insiders. Comparatively, 3.6% of Bloomsbury Publishing shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

HUTCHMED has a net margin of 163.84% compared to Bloomsbury Publishing's net margin of 8.28%. HUTCHMED's return on equity of 36.88% beat Bloomsbury Publishing's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	163.84%	36.88%	-5.90%
Bloomsbury Publishing	8.28%	12.74%	7.82%

In the previous week, Bloomsbury Publishing had 1 more articles in the media than HUTCHMED. MarketBeat recorded 1 mentions for Bloomsbury Publishing and 0 mentions for HUTCHMED. Bloomsbury Publishing's average media sentiment score of 0.75 beat HUTCHMED's score of 0.00 indicating that Bloomsbury Publishing is being referred to more favorably in the news media.

Company	Overall Sentiment
HUTCHMED	Neutral
Bloomsbury Publishing	Positive

Bloomsbury Publishing has a consensus target price of GBX 800, indicating a potential upside of 22.32%. Given Bloomsbury Publishing's stronger consensus rating and higher possible upside, analysts plainly believe Bloomsbury Publishing is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bloomsbury Publishing	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

HUTCHMED has a beta of 0.428, meaning that its share price is 57% less volatile than the broader market. Comparatively, Bloomsbury Publishing has a beta of 0.418, meaning that its share price is 58% less volatile than the broader market.

Summary

Bloomsbury Publishing beats HUTCHMED on 10 of the 16 factors compared between the two stocks.

How does Bloomsbury Publishing compare to Vectura Group?

Vectura Group (LON:VEC) and Bloomsbury Publishing (LON:BMY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, Bloomsbury Publishing had 1 more articles in the media than Vectura Group. MarketBeat recorded 1 mentions for Bloomsbury Publishing and 0 mentions for Vectura Group. Bloomsbury Publishing's average media sentiment score of 0.75 beat Vectura Group's score of 0.00 indicating that Bloomsbury Publishing is being referred to more favorably in the news media.

Company	Overall Sentiment
Vectura Group	Neutral
Bloomsbury Publishing	Positive

Bloomsbury Publishing has a net margin of 8.28% compared to Vectura Group's net margin of 0.00%. Bloomsbury Publishing's return on equity of 12.74% beat Vectura Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vectura Group	N/A	N/A	N/A
Bloomsbury Publishing	8.28%	12.74%	7.82%

Bloomsbury Publishing has a consensus price target of GBX 800, suggesting a potential upside of 22.32%. Given Bloomsbury Publishing's stronger consensus rating and higher possible upside, analysts plainly believe Bloomsbury Publishing is more favorable than Vectura Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vectura Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bloomsbury Publishing	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Vectura Group pays an annual dividend of GBX 38 per share. Bloomsbury Publishing pays an annual dividend of GBX 15.62 per share and has a dividend yield of 2.4%. Vectura Group pays out 189.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bloomsbury Publishing pays out 47.6% of its earnings in the form of a dividend. Bloomsbury Publishing is clearly the better dividend stock, given its higher yield and lower payout ratio.

42.2% of Bloomsbury Publishing shares are held by institutional investors. 3.6% of Bloomsbury Publishing shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Bloomsbury Publishing has higher revenue and earnings than Vectura Group. Vectura Group is trading at a lower price-to-earnings ratio than Bloomsbury Publishing, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vectura Group	£190.60M	0.00	N/A	£20.10	N/A
Bloomsbury Publishing	£325.90M	1.62	£37.37M	£32.80	19.94

Summary

Bloomsbury Publishing beats Vectura Group on 15 of the 15 factors compared between the two stocks.

How does Bloomsbury Publishing compare to Ergomed?

Bloomsbury Publishing (LON:BMY) and Ergomed (LON:ERGO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Bloomsbury Publishing presently has a consensus target price of GBX 800, indicating a potential upside of 22.32%. Given Bloomsbury Publishing's stronger consensus rating and higher probable upside, equities analysts clearly believe Bloomsbury Publishing is more favorable than Ergomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bloomsbury Publishing	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Bloomsbury Publishing has a beta of 0.418, meaning that its share price is 58% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

In the previous week, Bloomsbury Publishing had 1 more articles in the media than Ergomed. MarketBeat recorded 1 mentions for Bloomsbury Publishing and 0 mentions for Ergomed. Bloomsbury Publishing's average media sentiment score of 0.75 beat Ergomed's score of 0.00 indicating that Bloomsbury Publishing is being referred to more favorably in the media.

Company	Overall Sentiment
Bloomsbury Publishing	Positive
Ergomed	Neutral

Ergomed has a net margin of 9.87% compared to Bloomsbury Publishing's net margin of 8.28%. Ergomed's return on equity of 18.08% beat Bloomsbury Publishing's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bloomsbury Publishing	8.28%	12.74%	7.82%
Ergomed	9.87%	18.08%	10.16%

42.2% of Bloomsbury Publishing shares are held by institutional investors. Comparatively, 71.1% of Ergomed shares are held by institutional investors. 3.6% of Bloomsbury Publishing shares are held by insiders. Comparatively, 18.2% of Ergomed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bloomsbury Publishing has higher revenue and earnings than Ergomed. Ergomed is trading at a lower price-to-earnings ratio than Bloomsbury Publishing, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bloomsbury Publishing	£325.90M	1.62	£37.37M	£32.80	19.94
Ergomed	£152.09M	0.00	£15M	£0.29	N/A

Summary

Bloomsbury Publishing beats Ergomed on 8 of the 15 factors compared between the two stocks.

How does Bloomsbury Publishing compare to Amryt Pharma?

Bloomsbury Publishing (LON:BMY) and Amryt Pharma (LON:AMYT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

42.2% of Bloomsbury Publishing shares are held by institutional investors. 3.6% of Bloomsbury Publishing shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bloomsbury Publishing has higher revenue and earnings than Amryt Pharma. Amryt Pharma is trading at a lower price-to-earnings ratio than Bloomsbury Publishing, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bloomsbury Publishing	£325.90M	1.62	£37.37M	£32.80	19.94
Amryt Pharma	£210.24M	0.00	N/A	-£33.00	N/A

Bloomsbury Publishing currently has a consensus target price of GBX 800, suggesting a potential upside of 22.32%. Given Bloomsbury Publishing's stronger consensus rating and higher probable upside, equities research analysts plainly believe Bloomsbury Publishing is more favorable than Amryt Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bloomsbury Publishing	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Amryt Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Bloomsbury Publishing had 1 more articles in the media than Amryt Pharma. MarketBeat recorded 1 mentions for Bloomsbury Publishing and 0 mentions for Amryt Pharma. Bloomsbury Publishing's average media sentiment score of 0.75 beat Amryt Pharma's score of 0.00 indicating that Bloomsbury Publishing is being referred to more favorably in the media.

Company	Overall Sentiment
Bloomsbury Publishing	Positive
Amryt Pharma	Neutral

Bloomsbury Publishing has a net margin of 8.28% compared to Amryt Pharma's net margin of 0.00%. Bloomsbury Publishing's return on equity of 12.74% beat Amryt Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bloomsbury Publishing	8.28%	12.74%	7.82%
Amryt Pharma	N/A	N/A	N/A

Summary

Bloomsbury Publishing beats Amryt Pharma on 13 of the 13 factors compared between the two stocks.

Get Bloomsbury Publishing News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMY vs. The Competition

Export

Metric	Bloomsbury Publishing	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£519.82M	£12.57B	£7.37B	£2.54B
Dividend Yield	2.52%	2.61%	2.53%	6.17%
P/E Ratio	19.94	789.80	272.60	367.57
Price / Sales	1.62	764.53	624.33	83,481.74
Price / Cash	8.91	96.77	78.62	27.89
Price / Book	2.63	11.89	13.05	7.19
Net Income	£37.37M	£2.81B	£3.47B	£5.89B
7 Day Performance	-1.51%	1.77%	2.09%	0.30%
1 Month Performance	8.42%	3.85%	6.64%	3.31%
1 Year Performance	31.99%	6.56%	25.02%	22.13%

Bloomsbury Publishing Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMY Bloomsbury Publishing	3.6391 of 5 stars	GBX 654 +1.7%	GBX 800 +22.3%	+32.0%	£519.82M	£325.90M	19.94	34,300
INDV Indivior	N/A	GBX 1,238 +1.6%	N/A	+0.0%	£1.93B	£1.40B	N/A	1,000	News Coverage Gap Up High Trading Volume
HCM HUTCHMED	N/A	GBX 182.31 +0.7%	N/A	-23.0%	£1.58B	£549.12M	91.16	1,760	Gap Up
VEC Vectura Group	N/A	N/A	N/A	N/A	£1.01B	£190.60M	8.20	9,200
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:BMY) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bloomsbury Publishing (BMY) Competitors

BMY vs. INDV, HCM, VEC, ERGO, and AMYT

How does Bloomsbury Publishing compare to Indivior?

Summary

How does Bloomsbury Publishing compare to HUTCHMED?

Summary

How does Bloomsbury Publishing compare to Vectura Group?

Summary

How does Bloomsbury Publishing compare to Ergomed?

Summary

How does Bloomsbury Publishing compare to Amryt Pharma?

Summary

Media Sentiment Over Time

BMY vs. The Competition

Bloomsbury Publishing Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bloomsbury Publishing (BMY) Competitors

BMY vs. INDV, HCM, VEC, ERGO, and AMYT

How does Bloomsbury Publishing compare to Indivior?

Which has preferable valuation & earnings, INDV or BMY?

Do analysts rate INDV or BMY?

Is INDV or BMY more profitable?

Do institutionals and insiders hold more shares of INDV or BMY?

Does the media favor INDV or BMY?

Which has more risk & volatility, INDV or BMY?

Is INDV or BMY a better dividend stock?

Summary

How does Bloomsbury Publishing compare to HUTCHMED?

Which has higher earnings and valuation, HCM or BMY?

Do insiders & institutionals have more ownership in HCM or BMY?

Is HCM or BMY more profitable?

Does the media prefer HCM or BMY?

Do analysts prefer HCM or BMY?

Which has more volatility and risk, HCM or BMY?

Summary

How does Bloomsbury Publishing compare to Vectura Group?

Does the media refer more to VEC or BMY?

Is VEC or BMY more profitable?

Do analysts prefer VEC or BMY?

Is VEC or BMY a better dividend stock?

Do insiders & institutionals believe in VEC or BMY?

Which has preferable valuation and earnings, VEC or BMY?

Summary

How does Bloomsbury Publishing compare to Ergomed?

Do analysts rate BMY or ERGO?

Which has more volatility & risk, BMY or ERGO?

Does the media favor BMY or ERGO?

Is BMY or ERGO more profitable?

Do institutionals & insiders hold more shares of BMY or ERGO?

Which has preferable valuation & earnings, BMY or ERGO?

Summary

How does Bloomsbury Publishing compare to Amryt Pharma?

Do insiders & institutionals hold more shares of BMY or AMYT?

Which has better earnings and valuation, BMY or AMYT?

Do analysts prefer BMY or AMYT?

Does the media refer more to BMY or AMYT?

Is BMY or AMYT more profitable?

Summary

Media Sentiment Over Time

BMY vs. The Competition

Bloomsbury Publishing Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools